Top C-Suite Stories
Hims & Hers, Novo Nordisk strike GLP-1 partnership to end patent dispute
By Alan GoforthIn the United States, Him & Hers now plans to provide GLP-1 customers access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale.






